Drug Profile
Ormutivimab - Molecular Targeting Technologies/North China Pharmaceutical Corporation
Alternative Names: Anti-rabies monoclonal antibody - Molecular Targeting Technologies/North China Pharmaceutical Corporation; Human anti rabies mAb; NM-57; Recombinant human rabies monoclonal antibody - Molecular Targeting Technologies/North China Pharmaceutical Corporation; rhRIG - Molecular Targeting Technologies/North China Pharmaceutical Corporation; SO-57; SOJBLatest Information Update: 27 Feb 2024
Price :
$50
*
At a glance
- Originator Thomas Jefferson University
- Developer Molecular Targeting Technologies; North China Pharmaceutical Corporation
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Rabies